{
  "nctId": "NCT07178067",
  "briefTitle": "Longitudinal Evaluation of Short-Chain Fatty Acid Profiles During the Natural Disease Course and a Mediterranean Diet Intervention in Amyotrophic Lateral Sclerosis Patients",
  "officialTitle": "Short Chain Fatty Acids Profiles in Amyotrophic Lateral Sclerosis: Longitudinal Effects of Disease and Mediterranean Diet Intervention",
  "protocolDocument": {
    "nctId": "NCT07178067",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2025-09-03",
    "uploadDate": "2025-09-03T09:02",
    "size": 166466,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT07178067/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 44,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2022-07-21",
    "completionDate": "2023-11-30",
    "primaryCompletionDate": "2023-11-30",
    "firstSubmitDate": "2025-09-03",
    "firstPostDate": "2025-09-17"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Patients diagnosed with amyotrophic lateral sclerosis (ALS) in the past 12 months.\n* Disease duration of less than 1 year.\n* Fulfillment of the El Escorial diagnostic criteria (1996) for clinically probable or clinically definite ALS.\n\nExclusion Criteria:\n\n* Patients with an expected survival \\<18 months.\n* Presence of other neurodegenerative diseases.\n* Major comorbidities, such as: heart failure, cancer, autoimmune diseases, systemic diseases.\n* Gastrointestinal diseases that could influence gut microbiota.\n* Recent or ongoing treatment with antibiotics, probiotics, or prebiotics.\n* Low compliance with study procedures.",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Analysis of serum SCFA levels in ALS patients and healthy controls, and evaluating the change in circulating SCFA concentrations associated with Mediterranean diet intervention",
        "description": "This study compares plasma levels of short-chain fatty acids (SCFAs): acetic acid (ng/mL), propanoic acid (ng/mL), butyric acid (ng/mL), 3-OH butyric acid, 4-methyl-valeric acid (ng/mL) between adults with amyotrophic lateral sclerosis (ALS) and age/sex-matched healthy controls at baseline (T0) and then tracks how these levels change after 6 months of natural disease progression (T1) and 6 months after introducing a Mediterranean diet (T2) in ALS patients. Outcomes: Mean SCFA concentrations (±SD) (ng/mL) at T0 between-group (ALS vs control) differences at baseline, and within-patient changes over time to assess whether the Mediterranean diet is associated with favorable SCFA shifts (T0-T1, T1-T2).",
        "timeFrame": "12 months"
      }
    ],
    "secondary": [
      {
        "measure": "Association of Serum SCFA Levels With ALS Progression Measured by ALSFRS-R at T0, T1, and T2",
        "description": "The investigators analysed whether mean plasma levels of short-chain fatty acids (SCFAs)-acetate, propionate, butyrate, 3-hydroxybutyrate, hexanoate, and iso-hexanoate (ng/mL)-are associated with clinical progression of amyotrophic lateral sclerosis (ALS) (ALSFRS-R progression rate (ΔPR).",
        "timeFrame": "12 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 30,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T05:06:11.775Z",
  "dataSource": "ClinicalTrials.gov API v2 - Ultimate Complete Collection"
}